Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...
Hosted on MSN7d
Morgan Stanley Upgrades Gilead Sciences (GILD)Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Equal ...
In March, Gilead Sciences reported positive results for its ... in cancer trials – that equated to around 1.6 months of extra life, as well as improvements in quality of life measures, including ...
Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback